In one paragraphArticle in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 3 institutions in 1 country.
Antonio Tejera-MuñozMolecular and Cellular Biology in Renal and Vascular Pathology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Av Reyes Católicos 2, 28040 Madrid, Spain.ORCID 0000-0002-7954-5753 Isabel RodríguezCardiac Pathology Research Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0001-7213-1411 Álvaro Del Río-GarcíaCardiac Pathology Research Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0001-6048-958X Yamina MohamediCardiac Pathology Research Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
María MartínCardiac Pathology Research Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Valentina ChiminazzoBiostatistics and Epidemiology Platform, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Beatriz Suárez-ÁlvarezTranslational Immunology, Instituto de Investigación Sanitaria del Principado de Asturias ISPA, 33011 Oviedo, Spain.
Carlos López-LarreaTranslational Immunology, Instituto de Investigación Sanitaria del Principado de Asturias ISPA, 33011 Oviedo, Spain.
Marta Ruiz-OrtegaMolecular and Cellular Biology in Renal and Vascular Pathology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Av Reyes Católicos 2, 28040 Madrid, Spain.ORCID 0000-0002-1495-6535 Raúl R Rodrigues-DíezTranslational Immunology, Instituto de Investigación Sanitaria del Principado de Asturias ISPA, 33011 Oviedo, Spain.ORCID 0000-0002-2456-6709 Instituto de Investigación Sanitaria del Principado de Asturias · ESHospital Universitario Central de Asturias · ESUniversidad Autónoma de Madrid · ES
Funding
Instituto de Salud Carlos III (grant numbers PI20/000140 to MRO, PI18/00694 to IR, PI20/00639 to BSA and PI19/00184 to CLL)Instituto de Salud Carlos III Red de Investigación Renal RICORS2040 KIDNEY DISEASE (ISCIII): RD21/0005/0002 to MRO and RD21/0005/0017 to CLL. Sara Borrell program (grant number CD20/00042 to RRRD) and Miguel Servet program (grant number CP18/00106 to BSA) from ISCIIISociedad Española de Aterosclerosis Granto to RRRDSociedad Española de Cardiología SEC/FEC-INV-BAS22/014) to MROSociedad Española de Nefrología Grant to RRRD
6 · The paper itselfAbstract
Cellular communication network factor 2 (CCN2/CTGF) has been traditionally described as a downstream mediator of other profibrotic factors including transforming growth factor (TGF)-β and angiotensin II. However, recent evidence from our group demonstrated the direct role of CCN2 in maintaining aortic wall homeostasis and acute and lethal aortic aneurysm development induced by angiotensin II in the absence of CCN2 in mice. In order to translate these findings to humans, we evaluated the potential association between three polymorphisms in the
Indexed as
Aortic Aneurysm, ThoracicBicuspid Aortic Valve DiseaseAngiotensin IIAnimalsConnective Tissue Growth FactorHumansMiceRetrospective StudiesRisk FactorsAngiotensin IICCN2 protein, mouseConnective Tissue Growth Factoraneurysmascending aortaCCN2polymorphismvascular diseases
Identifiers
PMID36499730
PMCPMC9740045
OpenAlexW4311673598
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390